China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
April 9, 2015
New research shows the value of medical innovation is much higher than previously estimated.
March 17, 2015
How Canada is killing innovation in its pharmaceutical industry.
March 16, 2015
Smart regulatory reform focused on sectors that compete internationally can boost U.S. economic competitiveness while maintaining, or even increasing, social benefits.
March 9, 2015
To ensure the Trans-Pacific Partnership (TPP) Agreement creates a framework in which life sciences innovation flourishes throughout the TPP region, it needs to include 12 years of data protection for novel biologic drugs.
February 26, 2015
The National Institutes of Health needs greater resources and more funding stability.
February 17, 2015
IP protection is essential to future medical innovation.
January 8, 2015
Policymakers should be wary of adverse side effects when promoting competition for short-term consumer welfare.
January 7, 2015
New evidence demonstrates that IPRs have not decreased access to medicines.
April 10, 2014
To remain a leader in medical innovation, U.S. must strengthen research and IP.
March 17, 2014
What if innovation in life sciences stopped? A new study on Swedish healthcare provides insight.